Infusing biologic agents, such as infliximab and vedolizumab, for the treatment of IBD in a patient's home is becoming increasingly common. Smaller studies have raised concern about the safety of infusing biologic agents at home. However, the large-scale national experience with safety of home infusions has not been reported. Additionally, the patient experience with home infusions is unknown. Therefore, we conducted a mixed-methods study to better understand home infusions of infliximab and vedolizumab for patients with IBD.